Key Takeaways
- • VIG Partners, a South Korean mid-market buyout specialist, completed a tender offer for VIOL Co., Ltd. (a KOSDAQ-listed aesthetic medical device manufacturer) acquiring 28.49 million shares (48.77%) between June 18 and July 7, 2026.
- • VIG now holds an 83.52% total stake in VIOL, combining the tender offer acquisition with a previously agreed 34.76% stake from DMS, positioning the firm to initiate a comprehensive stock exchange delisting process.
- • The delisting mechanism requires VIG to hold over 67% of voting shares—a threshold already exceeded—enabling shareholders to vote on a special resolution that would exchange minority shares for parent company stock or cash compensation.
- • VIG plans to conduct regular open-market purchases at the tender offer price prior to executing the comprehensive stock exchange, with continued market purchases possible until transaction closing if shares remain available from DMS.
- • The acquisition represents a significant consolidation move by VIG Partners and follows the firm's temporary pause in international fundraising due to macroeconomic uncertainty tied to tariff and martial law concerns in South Korea.
Summary
VIG Partners, a leading domestic private equity fund manager specializing in mid-market buyouts, successfully concluded its tender offer for VIOL Co., Ltd. on July 7, 2026, acquiring 28.49 million common shares representing a 48.77% stake. The offer period ran from June 18 through July 7. According to the Financial Supervisory Service's electronic disclosure system, this acquisition brings VIG's total equity position in VIOL to 83.52% when combined with a previously agreed 34.76% stake (2.03 million shares) sourced from DMS.
VIOL operates as a KOSDAQ-listed aesthetic medical device manufacturer. The 83.52% aggregate holding now positions VIG above the 67% voting threshold required to initiate a comprehensive stock exchange—a delisting mechanism unique to South Korean capital markets. Under this framework, the controlling shareholder can propose a special resolution at a general shareholders' meeting to exchange minority shareholders' stock for shares in a newly created parent company or alternatively offer cash compensation.
VIG's acquisition strategy incorporates a measured approach to full equity consolidation. The firm intends to conduct regular open-market purchases at prices equivalent to the tender offer rate before initiating the comprehensive stock exchange process. If shares remain available from DMS through the transaction closing date, VIG will continue purchasing on the open market through that final date. This phased approach provides flexibility while maintaining pricing consistency for all remaining shareholders.
The VIOL transaction occurs within a broader context of VIG's strategic positioning. The firm recently paused international fundraising efforts temporarily due to market uncertainty stemming from tariff concerns and domestic political developments including martial law declarations in South Korea. Nevertheless, VIG has signaled intentions to resume overseas capital raising once market conditions stabilize, indicating continued confidence in deal execution and portfolio management capabilities during periods of macroeconomic volatility.
VIOL operates as a KOSDAQ-listed aesthetic medical device manufacturer. The 83.52% aggregate holding now positions VIG above the 67% voting threshold required to initiate a comprehensive stock exchange—a delisting mechanism unique to South Korean capital markets. Under this framework, the controlling shareholder can propose a special resolution at a general shareholders' meeting to exchange minority shareholders' stock for shares in a newly created parent company or alternatively offer cash compensation.
VIG's acquisition strategy incorporates a measured approach to full equity consolidation. The firm intends to conduct regular open-market purchases at prices equivalent to the tender offer rate before initiating the comprehensive stock exchange process. If shares remain available from DMS through the transaction closing date, VIG will continue purchasing on the open market through that final date. This phased approach provides flexibility while maintaining pricing consistency for all remaining shareholders.
The VIOL transaction occurs within a broader context of VIG's strategic positioning. The firm recently paused international fundraising efforts temporarily due to market uncertainty stemming from tariff concerns and domestic political developments including martial law declarations in South Korea. Nevertheless, VIG has signaled intentions to resume overseas capital raising once market conditions stabilize, indicating continued confidence in deal execution and portfolio management capabilities during periods of macroeconomic volatility.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.